MCID: PRD008
MIFTS: 64

Periodontitis

Categories: Blood diseases, Gastrointestinal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Periodontitis

MalaCards integrated aliases for Periodontitis:

Name: Periodontitis 12 74 29 6 43 15 17 71
Chronic Pericementitis 12
Chronic Periodontitis 71

Classifications:



External Ids:

Disease Ontology 12 DOID:824
MeSH 43 D010518
NCIt 49 C34918
SNOMED-CT 67 41565005
ICD10 32 K05.3
UMLS 71 C0031099 C0266929

Summaries for Periodontitis

MalaCards based summary : Periodontitis, also known as chronic pericementitis, is related to periodontitis, chronic and periodontitis, aggressive, 1, and has symptoms including leukorrhea and purulent discharge. An important gene associated with Periodontitis is CDKN2B-AS1 (CDKN2B Antisense RNA 1), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Risedronate and Menthol have been mentioned in the context of this disorder. Affiliated tissues include bone, neutrophil and endothelial, and related phenotypes are homeostasis/metabolism and immune system

Wikipedia : 74 Periodontal disease, also known as gum disease, is a set of inflammatory conditions affecting the... more...

Related Diseases for Periodontitis

Diseases in the Periodontitis family:

Periodontitis, Chronic Susceptibility to Localized Juvenile Periodontitis

Diseases related to Periodontitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1377)
# Related Disease Score Top Affiliating Genes
1 periodontitis, chronic 35.1 TNFSF11 TNFRSF11B MMP8 MMP1 IL6 IL1B
2 periodontitis, aggressive, 1 35.1 MMP8 MMP1 IL1A FPR1 CTSC
3 chronic apical periodontitis 34.3 TNFSF11 TNFRSF11B MIR146A
4 periapical periodontitis 34.1 TNFSF11 TNFRSF11B TNF TLR2 MMP9 MMP8
5 acute pericementitis 33.8 TNFSF11 TLR2 IL1B
6 aggressive periodontitis 33.7 TNFSF11 TNFRSF11B TNF TLR4 TLR2 PDON2
7 gingivitis 33.1 TNF TLR2 MMP9 MMP8 MMP1 IL6
8 gingival recession 32.5 MMP8 IL6 IL1B
9 bone resorption disease 32.2 TNFSF11 TNFRSF11B TNF IL6 IL1B CTSK
10 ankylosis 32.0 TNFSF11 TNFRSF11B TNF CRP
11 root resorption 31.9 TNFSF11 TNFRSF11B MMP9 IL6 IL1B IL1A
12 gingival overgrowth 31.7 TNF MMP8 MMP1 IL6 IL1A CXCL8
13 pustulosis of palm and sole 31.4 TNF CXCL8 CRP
14 atherosclerosis susceptibility 31.3 TNF TLR4 MMP9 IL6 IL1B CXCL8
15 liver disease 31.3 TNF IL6 IL1B IL1A CXCL8
16 osteonecrosis 31.3 TNFSF11 TNFRSF11B TNF MMP8 IL1B IL10
17 stomatitis 31.3 TNF TLR4 IL6 IL1B IL10 CXCL8
18 infective endocarditis 31.3 TNF TLR2 IL6 CRP
19 pulpitis 31.3 TNF TLR4 MMP1 IL6 IL1B IL1A
20 pre-eclampsia 31.2 TNF TLR4 MMP9 IL6 IL1B IL10
21 neutropenia 31.2 TNF TLR4 IL6 IL1B IL10 CXCL8
22 tooth resorption 31.2 TNFSF11 TNFRSF11B IL1B CTSK
23 acquired immunodeficiency syndrome 31.2 TNF IL6 IL1B IL10 CRP
24 juvenile arthritis 31.1 IL6 IL10 CXCL8 CRP
25 sclerosteosis 31.1 TNFSF11 TNFRSF11B CTSK
26 peptic ulcer disease 31.1 TNF IL1B IL10 CXCL8
27 acute myocardial infarction 31.1 TNF MMP9 IL6 CRP CDKN2B-AS1
28 lichen planus 31.1 TNF TLR2 IL6 IL10 CXCL8
29 periapical granuloma 31.1 TNFSF11 TLR2 MMP8 CXCL8
30 cyclic neutropenia 31.1 TNF IL1B CXCL8
31 endocarditis 31.1 TNF TLR2 IL6 IL1A IL10 CXCL8
32 arteries, anomalies of 31.1 TNF MIR146A IL6 IL1B CRP
33 cerebrovascular disease 31.1 TNF TLR4 MMP9 IL6 CRP
34 chronic kidney disease 31.1 TNFSF11 TNFRSF11B TNF TLR4 MMP9 IL6
35 spondylitis 31.1 TNFSF11 TNF IL6 IL10 CRP
36 aortic aneurysm 31.1 MMP9 IL6 CRP CDKN2B-AS1
37 gastritis 31.0 TNF TLR4 IL6 IL1B IL10 CXCL8
38 pericoronitis 31.0 IL1B CRP
39 sleep apnea 31.0 TNF IL6 IL1B IL10 CXCL8 CRP
40 anxiety 31.0 TNF IL6 IL1B CRP
41 spondyloarthropathy 1 31.0 TNFSF11 TNFRSF11B TNF TLR4 CRP
42 systemic scleroderma 31.0 TNF IL6 IL1B IL10 CRP
43 immune deficiency disease 31.0 TNF TLR2 IL6 IL1A IL10
44 fatty liver disease 31.0 TNF TLR4 IL6 IL1B IL1A CXCL8
45 juvenile rheumatoid arthritis 30.9 TNF IL6 IL1B IL10 CXCL8 CRP
46 bacterial infectious disease 30.9 TNF TLR4 TLR2 IL6 IL1B IL1A
47 bone disease 30.9 TNFSF11 TNFRSF11B TNF MMP9 IL6 IL1B
48 haemophilus influenzae 30.9 TNF TLR2 CXCL8
49 systemic autoimmune disease 30.9 MMP9 IL6 CRP
50 osteogenic sarcoma 30.9 TNFSF11 TNFRSF11B TNF MMP9 IL6 CDKN2B-AS1

Graphical network of the top 20 diseases related to Periodontitis:



Diseases related to Periodontitis

Symptoms & Phenotypes for Periodontitis

UMLS symptoms related to Periodontitis:


leukorrhea, purulent discharge

MGI Mouse Phenotypes related to Periodontitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.28 CRP CTSC CTSK FPR1 IL10 IL1A
2 immune system MP:0005387 10.27 CRP CTSC CTSK FPR1 IL10 IL1A
3 hematopoietic system MP:0005397 10.25 CTSC CTSK FPR1 IL10 IL1A IL1B
4 cardiovascular system MP:0005385 10.16 CRP IL10 IL1A IL1B IL6 MMP9
5 integument MP:0010771 10.02 CTSC IL10 IL1A IL1B IL6 MMP9
6 neoplasm MP:0002006 9.9 IL10 IL1A IL1B IL6 MMP1 MMP8
7 limbs/digits/tail MP:0005371 9.8 CTSK IL10 MMP9 TLR4 TNF TNFRSF11B
8 respiratory system MP:0005388 9.56 CTSK IL10 IL6 MMP9 TLR2 TLR4
9 skeleton MP:0005390 9.32 CTSK IL10 IL1B IL6 MMP9 TLR2

Drugs & Therapeutics for Periodontitis

Drugs for Periodontitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 390)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
2
Menthol Approved Phase 4 2216-51-5 16666
3
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
4
Alendronate Approved Phase 4 66376-36-1, 121268-17-5 2088
5
Atorvastatin Approved Phase 4 134523-00-5 60823
6
Azithromycin Approved Phase 4 83905-01-5 447043 55185
7
Montelukast Approved Phase 4 158966-92-8 5281040
8
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
9
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
10
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
11
Polyestradiol phosphate Approved Phase 4 28014-46-2
12
Turmeric Approved, Experimental, Investigational Phase 4
13
Zoledronic Acid Approved Phase 4 118072-93-8 68740
14 sodium fluoride Approved Phase 4 7681-49-4
15
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
16
Lovastatin Approved, Investigational Phase 4 75330-75-5 53232
17
Albendazole Approved, Vet_approved Phase 4 54965-21-8 2082
18
Clarithromycin Approved Phase 4 81103-11-9 84029
19
Ethanol Approved Phase 4 64-17-5 702
20
Coal tar Approved Phase 4 8007-45-2
21
Curcumin Approved, Experimental, Investigational Phase 4 458-37-7 969516
22
Triclosan Approved, Investigational Phase 4 3380-34-5 5564
23
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
24
Acetaminophen Approved Phase 4 103-90-2 1983
25
Hexetidine Approved, Investigational Phase 4 141-94-6
26
Simvastatin Approved Phase 4 79902-63-9 54454
27
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
28
Racepinephrine Approved Phase 4 329-65-7 838
29
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
30
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
31
Zinc Approved, Investigational Phase 4 7440-66-6 32051
32
Zinc oxide Approved Phase 4 1314-13-2
33
Eugenol Approved Phase 4 97-53-0 3314
34
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
35
Edetic Acid Approved, Vet_approved Phase 4 60-00-4, 62-33-9 6049
36
Pentetic acid Approved Phase 4 67-43-6
37
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
38
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
39
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
40
Ibuprofen Approved Phase 4 15687-27-1 3672
41
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
42
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
43
Phenothiazine Experimental, Vet_approved Phase 4 92-84-2
44 calcium channel blockers Phase 4
45 Propolis Phase 4
46 Bee Products Phase 4
47 Adjuvants, Immunologic Phase 4
48 Immunologic Factors Phase 4
49 N-Methylaspartate Phase 4
50 Tolonium Chloride Phase 4

Interventional clinical trials:

(show top 50) (show all 1029)
# Name Status NCT ID Phase Drugs
1 Custom Tray Application of Peroxide Gel as an Adjunct to Scaling and Root Planing in the Treatment of Periodontitis: A 6-Month Randomized Trial Unknown status NCT03262701 Phase 4 Hydrogen Peroxide Gel, 13 weeks;Hydrogen Peroxide Gel, 26 weeks
2 Photodynamic Disinfection in Combination With Scaling and Root Planing in the Treatment of Chronic Periodontitis Unknown status NCT00297531 Phase 4
3 Clinical Outcomes Following Non-Surgical Treatment of Chronic Periodontitis, Using Scaling and Root Planing (SRP) in Conjunction With PerioWave, Compared to SRP Alone Unknown status NCT00296881 Phase 4
4 Effect of Probiotic Lactobacillus Reuteri-containing Lozenges (Prodentis) on Halitosis in Patients With Chronic Periodontitis Unknown status NCT02789436 Phase 4 L. reuteri Prodentis® lozenges
5 Clinical and Microbiological Effects of an Essential Oils Solution Used as an Adjunct to Daily Oral Hygiene Practices in Chronic Periodontitis Patients in Supportive Care Unknown status NCT01195493 Phase 4
6 Metronidazole and Amoxicillin as Adjuncts to Scaling and Root Planing for the Treatment of Type 2 Diabetic Subjects With Periodontitis: a Randomized Placebo-controlled Clinical Trial Unknown status NCT02135952 Phase 4 MTZ+AMX
7 Filling of Periodontal Pockets With a Commercially Available Injectable Cross-linked Hyaluronic Acid Dental Filler Versus Oral Hygiene Alone, After Scaling and Root Planing and Chlorhexidine Disinfection, for the Treatment of Periodontitis: A Single-blinded, Multi Center, Prospective, Randomized Controlled Trial Unknown status NCT02391974 Phase 4
8 Clinical, Microbiological and Biochemical Effects of the Antimicrobial Photodynamic Therapy Unknown status NCT01532674 Phase 4
9 Evaluating the Adjunctive Effect of Stress Reduction Protocol in the Non-Surgical Periodontal Therapy of Chronic Periodontitis Subjects Associated With Stress: A Randomized Control Pilot Study Unknown status NCT02487862 Phase 4
10 Effect of Actonel on Periodontal Health of Postmenopausal Women Unknown status NCT00594334 Phase 4 Risedronate
11 A Clinical and Radiographic Evaluation of DFDBA (Demineralised Freeze Dried Bone Allograft) With Amniotic Membrane (AM) in the Treatment of Periodontal Osseous Defects-12 Month Randomized Controlled Clinical Trial Unknown status NCT02635529 Phase 4
12 Antiplaque Effect of Essential Oils and 0.2% Chlorhexidine on an in Situ Model of Oral Biofilm Growth. A Randomized Clinical Trial Unknown status NCT02946801 Phase 4 Essential oils;Essential oils without alcohol;Sterile water
13 Methodology of Application and Immediate Effect of the Essential Oils and 0.2% Chlorhexidine on Oral Biofilm: Immersion Versus Mouthwash. Unknown status NCT02267239 Phase 4 essential oils, immersion;Chlorhexidine, immersion;essential oils, mouthwash;chlorhexidine, mouthwash
14 The Treatment of Periodontal Diseases. A Randomized, Blinded, Five Years Follow-up, Four-arm, Placebo Controlled Clinical Intervention Trial Unknown status NCT01318928 Phase 4 Metronidazol
15 Essential Oils With and Without Alcohol: in Vivo Antibacterial Effect Unknown status NCT03146390 Phase 4 Essential oils;Alcohol free essential oils
16 Effect of Scaling & Root Planing (SRP) Combined With Therapy Of Omega-3 Fatty Acid on Clinical Parameters and Serum Levels of C-Reactive Protein (CRP) in Chronic Periodontitis - A Randomised Control Trial. Completed NCT01997853 Phase 4 Omega 3 fatty acid;Placebo
17 EFFECT OF SRP WITH ADJUNCTIVE THERAPY OF HERBAL IMMUNOMODULATORS ON THE SERUM C REACTIVE PROTEIN (CRP) LEVELS & CLINICAL PARAMETERS IN CHRONIC PERIODONTITIS PATIENTS - A RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, CLINICAL TRIAL. Completed NCT01997814 Phase 4 herbal immunomodulator;Placebo
18 The Effects of Non -Surgical Periodontal Therapy on Glycemic Control and Periodontal Health in Diabetic Patients With Periodontitis (Randomized Controlled Clinical Trial) Completed NCT03783845 Phase 4
19 "Effect of Scaling and Root Planing on Liver Function Test (Alanine Aminotransferase and Aspartate Aminotransferase) in Systemically Healthy - Chronic Periodontitis Subjects: a Clinical Trial." Completed NCT02583841 Phase 4
20 The Effect Of SRP With Adjunctive Systemic Therapy Of Leukotriene Receptor Antagonist-Montelukast On The Serum C Reactive Protein Levels & Clinical Parameters In Chronic Periodontitis Patients - A Randomized Controlled Trial Completed NCT02014532 Phase 4 Montelukast;Placebo
21 Comparison of Moxifloxacin With Ciprofloxacin/Metronidazole as Adjunctive Therapy to Mechanical Treatment of Patients With Chronic Periodontitis Completed NCT00805558 Phase 4 moxifloxacin;Ciprofloxacin plus metronidazole
22 The Response of Periodontal Pathogens to the Respective or Combined Treatment of Scaling and Root Planning and Locally Delivered Minocycline in Patients With Chronic Periodontitis- a Short-term Randomized Clinical Trial Completed NCT02355977 Phase 4 minocycline
23 Effects of the Variation in the Time of Systemic Administration of Metronidazole and Amoxicillin Associated to the Non-surgical Therapy of Chronic Periodontitis. Completed NCT01211223 Phase 4 Administration of Metronidazole plus Amoxicillin
24 A Multicenter, Randomized, Examiner Blinded Study of Photoactivated Disinfection With Scaling and Root Planing in the Treatment of Chronic Periodontitis Completed NCT00297518 Phase 4
25 Efficacy of Adjunctive Photodynamic Therapy in Non-surgical Treatment of Chronic Periodontitis: a Randomized , Controlled Clinical Trial Completed NCT01034501 Phase 4
26 "Efficacy of Nonsurgical Periodontal Therapy in Patients With Chronic Renal Disease and Periodontitis: A Biochemical and Microbiological Assay" Completed NCT02901743 Phase 4
27 Long-term Safety Evaluation of Minocycline Resistance After Treatment With Minocycline HCl Microspheres, 1 mg in Subjects With Chronic Periodontitis Completed NCT00668746 Phase 4 Minocycline HCl microspheres
28 Effect of Scaling and Root Planing Along With Topical Application of Commercially Available Curcuma Longa Gel on Superoxide Dismutase and Malondialdehyde Levels in Saliva of Chronic Periodontitis Patients Completed NCT02442453 Phase 4 Topical application of curenext gel;Placebo
29 Local Drug Delivery of Aloe Vera Gel in Chronic Periodontitis Patients With Controlled Diabetes Mellitus Completed NCT02437747 Phase 4 SRP + Aloe
30 Effect of Periodontal Therapy and Bisphosphonates on Gingival Crevicular Fluid Levels of Nuclear Factor- κb Ligand (RANKL) and Osteoprotegerin in Postmenopausal Osteoporosis: Results of a 12-Month Study Completed NCT02808988 Phase 4
31 Comparative Evaluation of Treatment Of Infrabony Defects With and Without 1.2% Rosuvastatin Gel: In-Vivo Study Completed NCT03677297 Phase 4 Rosuvastatin
32 Systemic Lycopene as an Adjunct to Scaling and Rootplaning in Chronic Periodontitis Patients With Type 2 Diabetes Mellitus Completed NCT02263352 Phase 4 Lycored soft gels Jagsonpal Pharma, Systemic 8mgms/day
33 Effect of Arthrospira Platensis (Spirulina) as an Adjunct to Scaling and Root Planing on Salivary Antioxidant Levels in Chronic Periodontitis Subjects Completed NCT02886676 Phase 4 Spirulina capsules
34 Evaluation of Gingival Crevicular Fluid Transforming Growth Factor-β1 Level After Treatment of Intrabony Periodontal Defects With Enamel Matrix Derivatives and Autogenous Bone Graft Completed NCT02218515 Phase 4
35 "Comparative Evaluation Of The Efficacy Of Atorvastatin Gel As An Adjunct To Allografts In The Treatment Of Intrabony Defects" - A Clinico Radiological Study Completed NCT03009097 Phase 4 DFDBA with atorvastatin
36 The Use of Simvastatin Gel With Perforated Resorbable Membranes in the Treatment of Intrabony Defects in Chronic Periodontitis Patients (Clinical and Biochemical Study) Completed NCT03419429 Phase 4 Simvastatin
37 Local Minocycline to Reduce Future Inflammation and Bone Loss in Periodontal Maintenance Patients Completed NCT01647282 Phase 4 locally-applied minocycline HCl (1 mg)
38 Moxifloxacin In Situ Gel as an Adjunct in the Treatment of Periodontal Pocket: A Randomized Clinical Trial. Completed NCT02016157 Phase 4 Moxifloxacin
39 Impact of Periodontal Treatment on Serum Levels of Hepcidin and Hemoglobin: a Clinical Trial Completed NCT02641210 Phase 4 Albendazole
40 Full-mouth and Partial-mouth Scaling and Root Planing in Type 2 Diabetic Subjects: Clinical, Immunological and Microbiological Outcomes Completed NCT02062047 Phase 4 Chlorhexidine
41 Efficacy of Clarithromycin is an Adjunct to Scaling and Root Planing .A Clinical Microbiological and Immunological Study. Completed NCT02359721 Phase 4 tablet clarithromycin 500 mg (Clarino-500) orally
42 Evaluation of PLGA Microspheres Loaded With Doxycycline Associated to Periodontal Debridement in the Treatment of Chronic Advanced Periodontitis. Completed NCT02487186 Phase 4 Doxicicline
43 Antimicrobial Therapy as Adjunct to Periodontal Treatment: Effect of Timing on Clinical, Microbiological and Systemic Response Completed NCT02197260 Phase 4 3/d 500 mg metronidazole plus 375 mg amoxicillin for 7 days
44 Comparison of Ofloxacin and Metronidazole/Amoxicillin on the Treatment of Periodontitis. Completed NCT04353362 Phase 4 Ofloxacin;Amoxicillin;Metronidazole
45 Investigation of the Effects of Bisphosphonate on the Gingival Crevicular Fluid Levels of Sclerostin and the DKK-1 in Individuals With Postmenopausal Osteoporosis With Periodontal Changes Completed NCT04149405 Phase 4 bisphosphonate therapy
46 Propolis Improves Periodontal Status and Glycemic Control in Subjects With Type 2 Diabetes Mellitus and Chronic Periodontitis: a Randomized Clinical Trial Completed NCT02794506 Phase 4 Propolis;Placebo
47 Effects of 1% Sodium Alendronate in Non Surgical Periodontal Therapy on Clinical and Tomographical Parameters: a Randomized Placebo Controlled 6-month Clinical Trial Completed NCT02470611 Phase 4 Sodium alendronate
48 Clinical and Microbiological Effects of Adjunctive Metronidazole Plus Amoxicillin in the Treatment of Generalized Chronic Periodontitis: Smokers Versus Non-Smokers. Completed NCT01837199 Phase 4 Metronidazole plus Amoxicillin
49 Effects of Photodynamic Therapy on Clinical and Immunological Parameters in a Group of Periodontal Patients Undergoing Supportive Periodontal Therapy Completed NCT02666573 Phase 4
50 Estimation of Interleukin-21 Levels in Gingival Crevicular Fluid in Patients With Periodontal Health and Disease Following Non-surgical Periodontal Therapy: A Clinico-biochemical Study Completed NCT02861937 Phase 4

Search NIH Clinical Center for Periodontitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


carbamide peroxide

Cochrane evidence based reviews: periodontitis

Genetic Tests for Periodontitis

Genetic tests related to Periodontitis:

# Genetic test Affiliating Genes
1 Periodontitis 29

Anatomical Context for Periodontitis

MalaCards organs/tissues related to Periodontitis:

40
Bone, Neutrophil, Endothelial, Testes, Heart, T Cells, Monocytes

Publications for Periodontitis

Articles related to Periodontitis:

(show top 50) (show all 25697)
# Title Authors PMID Year
1
Minocycline-loaded PLGA electrospun membrane prevents alveolar bone loss in experimental peridontitis. 61
31913739 2020
2
MicroRNA-210 protects against periodontitis through targeting HIF-3α and inhibiting p38MAPK/NF-κB pathway. 61
31852255 2020
3
Assessment of Inhibition of Biofilm Formation on TiO₂ Nanotubes According to Non-Thermal Plasma Treatment Conditions and the Elapsed Time in the Atmosphere. 61
32331171 2020
4
Baicalin inhibits root resorption during tooth movement in a rodent model. 61
32470833 2020
5
Metformin ameliorates the NLPP3 inflammasome mediated pyroptosis by inhibiting the expression of NEK7 in diabetic periodontitis. 61
32480011 2020
6
A biochemical and immunohistochemical study of the effects of caffeic acid phenethyl ester on alveolar bone loss and oxidative stress in diabetic rats with experimental periodontitis. 61
32013634 2020
7
Drug delivery based pharmacological enhancement and current insights of quercetin with therapeutic potential against oral diseases. 61
32521458 2020
8
Is there association between stress and periodontitis? 61
31654249 2020
9
A low level of lysophosphatidic acid in human gingival crevicular fluid from patients with periodontitis due to high soluble lysophospholipase activity: Its potential protective role on alveolar bone loss by periodontitis. 61
32179099 2020
10
Association between periodontitis and pulmonary function based on the Third National Health and Nutrition Examination Survey (NHANES III). 61
32390194 2020
11
Dynamic microstructural changes in alveolar bone in ligature-induced experimental periodontitis. 61
31713702 2020
12
The biofilm-associated bacterial infections unrelated to indwelling devices. 61
32150327 2020
13
Analysis of subgingival microbiome of periodontal disease and rheumatoid arthritis in Chinese: A case-control study. 61
32565704 2020
14
Identification of putative genetic modifying factors that influence the development of Papillon-Lefévre or Haim-Munk syndrome phenotypes. 61
31925812 2020
15
Single-Cell Analysis of the Periodontal Immune Niche in Type 2 Diabetes. 61
32186942 2020
16
Effects of Sulfonylureas on Periodontopathic Bacteria-Induced Inflammation. 61
32202959 2020
17
Porphyromonas gingivalis Induces Insulin Resistance by Increasing BCAA Levels in Mice. 61
32176550 2020
18
Thymoquinone inhibits biofilm formation and virulence properties of periodontal bacteria. 61
32416351 2020
19
Tripartite motif 31 alleviates IL-1ß secretion via promoting the ubiquitination of pyrin domain domains-containing protein 3 in human periodontal ligament fibroblasts. 61
32323100 2020
20
Attenuated regenerative properties in human periodontal ligament-derived stem cells of older donor ages with shorter telomere length and lower SSEA4 expression. 61
32043210 2020
21
Cryotherapy: A New Paradigm of Treatment in Endodontics. 61
32386857 2020
22
In vivo accuracy of dental magnetic resonance imaging in assessing maxillary molar furcation involvement: A feasibility study in humans. 61
32343861 2020
23
Effectiveness of a reciprocating single file, single cone endodontic treatment approach: a randomized controlled pragmatic clinical trial. 61
31650315 2020
24
Association of DNA sequence-independent genetic regulatory mechanisms with apical periodontitis: A scoping review. 61
32387743 2020
25
Anticardiolipin from Periodontitis Patients Impact Fetal Loss and Annexin V. 61
32202953 2020
26
The correspondence of 3D supporting bone loss and crown-to-root ratio to periodontitis classification. 61
32319127 2020
27
Effect of self-performed mechanical plaque control frequency on gingival health in subjects with a history of periodontitis: A Randomized Clinical Trial. 61
32315448 2020
28
Association of polymorphisms in TNF-α, IL-1β, GSTM and GSTT genes with apical periodontitis: is there a link with herpesviral infection? 61
32216135 2020
29
Effect of periodontal therapy on adipokine biomarkers in overweight. 61
32248552 2020
30
Studies on effects of umbelliferon derivatives against periodontal bacteria; antibiofilm, inhibition of quorum sensing and molecular docking analysis. 61
32304793 2020
31
Characterization of the subgingival microbiota in the peritoneal dialysis patients with periodontitis. 61
32416352 2020
32
Oral spirochetes: Pathogenic mechanisms in periodontal disease. 61
32304795 2020
33
Periodontitis and oral Cancer-A striking link. 61
32147310 2020
34
IL-10 secreting B cells regulate periodontal immune response during periodontitis. 61
31701299 2020
35
Identification of immune-related lncRNAs in periodontitis reveals regulation network of gene-lncRNA-pathway-immunocyte. 61
32417654 2020
36
Periodontitis lesions in smokers and non-smokers. 61
32304269 2020
37
Periodontitis and Hypertension: Is the Association Causal? 61
32500479 2020
38
Neutrophil Extracellular Traps in Periodontitis. 61
32575367 2020
39
Antimicrobial photodynamic therapy efficacy against specific pathogenic periodontitis bacterial species. 61
32087294 2020
40
Association between periodontitis and metabolic syndrome: A case-control study. 61
31691971 2020
41
Proteomics approach for biomarkers and diagnosis of periodontitis: systematic review. 61
32529063 2020
42
Mesenchymal stem cell-based tissue regeneration therapies for periodontitis. 61
31970269 2020
43
The anti-periodontitis action of metformin via targeting NLRP3 inflammasome. 61
32305805 2020
44
Oral Microbiome and Gingival Transcriptome Profiles of Ligature-Induced Periodontitis. 61
32075482 2020
45
Epstein-Barr virus-infected plasma cells in periodontitis lesions. 61
32165332 2020
46
Treatment of periodontitis reduces systemic inflammation in type 2 diabetes. 61
32106333 2020
47
Periodontitis and airflow limitation in older Swedish individuals. 61
32246489 2020
48
[Efficacy of clarithromycin in the adjuvant treatment of chronic periodontitis: a Meta-analysis]. 61
32573137 2020
49
Anti-heat shock protein 70 levels in gingival crevicular fluid of Japanese patients with chronic periodontitis. 61
32493865 2020
50
Microbial and metabolomic analysis of gingival crevicular fluid in general chronic periodontitis patients: lessons for a predictive, preventive, and personalized medical approach. 61
32547651 2020

Variations for Periodontitis

ClinVar genetic disease variations for Periodontitis:

6 (show all 45) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CTSK NM_000396.4(CTSK):c.905G>A (p.Trp302Ter)SNV Conflicting interpretations of pathogenicity 684727 1:150769360-150769360 1:150796884-150796884
2 FPR1 NM_002029.3(FPR1):c.674C>T (p.Ala225Val)SNV Uncertain significance 526509 rs141913828 19:52249574-52249574 19:51746321-51746321
3 FPR1 NC_000019.10:g.(?_51745922)_(51759909_?)dupduplication Uncertain significance 831452 19:52249175-52263162
4 FPR1 NM_002029.4(FPR1):c.955A>C (p.Ser319Arg)SNV Uncertain significance 847520 19:52249293-52249293 19:51746040-51746040
5 FPR1 NM_002029.4(FPR1):c.952G>A (p.Ala318Thr)SNV Uncertain significance 840695 19:52249296-52249296 19:51746043-51746043
6 FPR1 NM_002029.4(FPR1):c.934C>T (p.Leu312=)SNV Uncertain significance 848388 19:52249314-52249314 19:51746061-51746061
7 FPR1 NM_002029.4(FPR1):c.898C>G (p.Leu300Val)SNV Uncertain significance 835264 19:52249350-52249350 19:51746097-51746097
8 FPR1 NM_002029.4(FPR1):c.826T>C (p.Tyr276His)SNV Uncertain significance 852538 19:52249422-52249422 19:51746169-51746169
9 FPR1 NM_002029.4(FPR1):c.736G>T (p.Val246Phe)SNV Uncertain significance 836559 19:52249512-52249512 19:51746259-51746259
10 FPR1 NM_002029.4(FPR1):c.713G>A (p.Arg238His)SNV Uncertain significance 844349 19:52249535-52249535 19:51746282-51746282
11 FPR1 NM_002029.4(FPR1):c.613C>T (p.Arg205Trp)SNV Uncertain significance 851750 19:52249635-52249635 19:51746382-51746382
12 FPR1 NM_002029.4(FPR1):c.570G>C (p.Arg190Ser)SNV Uncertain significance 856172 19:52249678-52249678 19:51746425-51746425
13 FPR1 NM_002029.4(FPR1):c.440T>C (p.Ile147Thr)SNV Uncertain significance 841167 19:52249808-52249808 19:51746555-51746555
14 FPR1 NM_002029.4(FPR1):c.331G>A (p.Gly111Arg)SNV Uncertain significance 860414 19:52249917-52249917 19:51746664-51746664
15 FPR1 NM_002029.4(FPR1):c.79A>G (p.Ile27Val)SNV Uncertain significance 841693 19:52250169-52250169 19:51746916-51746916
16 FPR1 NM_002029.4(FPR1):c.40G>A (p.Gly14Arg)SNV Uncertain significance 838179 19:52250208-52250208 19:51746955-51746955
17 FPR1 NM_002029.3(FPR1):c.827A>G (p.Tyr276Cys)SNV Uncertain significance 526508 rs1555796364 19:52249421-52249421 19:51746168-51746168
18 FPR1 NM_002029.3(FPR1):c.805C>T (p.Arg269Cys)SNV Uncertain significance 575332 rs771446051 19:52249443-52249443 19:51746190-51746190
19 FPR1 NM_002029.3(FPR1):c.409C>T (p.Arg137Cys)SNV Uncertain significance 575041 rs139132326 19:52249839-52249839 19:51746586-51746586
20 FPR1 NM_002029.3(FPR1):c.534T>A (p.Phe178Leu)SNV Uncertain significance 566652 rs747450344 19:52249714-52249714 19:51746461-51746461
21 FPR1 NM_002029.3(FPR1):c.710G>A (p.Ser237Asn)SNV Uncertain significance 641997 19:52249538-52249538 19:51746285-51746285
22 FPR1 NM_002029.3(FPR1):c.559C>T (p.Pro187Ser)SNV Uncertain significance 640589 19:52249689-52249689 19:51746436-51746436
23 FPR1 NM_002029.3(FPR1):c.542C>T (p.Ser181Leu)SNV Uncertain significance 660454 19:52249706-52249706 19:51746453-51746453
24 FPR1 NM_002029.3(FPR1):c.511A>C (p.Thr171Pro)SNV Uncertain significance 646664 19:52249737-52249737 19:51746484-51746484
25 FPR1 NM_002029.3(FPR1):c.439A>G (p.Ile147Val)SNV Uncertain significance 651669 19:52249809-52249809 19:51746556-51746556
26 FPR1 NM_002029.3(FPR1):c.379G>A (p.Val127Ile)SNV Uncertain significance 652351 19:52249869-52249869 19:51746616-51746616
27 FPR1 NM_002029.3(FPR1):c.274C>A (p.Pro92Thr)SNV Uncertain significance 656419 19:52249974-52249974 19:51746721-51746721
28 FPR1 NM_002029.3(FPR1):c.205G>A (p.Val69Met)SNV Uncertain significance 660114 19:52250043-52250043 19:51746790-51746790
29 FPR1 NM_002029.3(FPR1):c.198C>A (p.Asn66Lys)SNV Uncertain significance 660315 19:52250050-52250050 19:51746797-51746797
30 FPR1 NM_002029.3(FPR1):c.26C>T (p.Thr9Met)SNV Likely benign 456364 rs148095693 19:52250222-52250222 19:51746969-51746969
31 FPR1 NM_002029.3(FPR1):c.607A>G (p.Ile203Val)SNV Likely benign 783851 19:52249641-52249641 19:51746388-51746388
32 FPR1 NM_002029.3(FPR1):c.368G>A (p.Arg123His)SNV Likely benign 785829 19:52249880-52249880 19:51746627-51746627
33 FPR1 NM_002029.3(FPR1):c.744A>C (p.Ala248=)SNV Likely benign 716687 19:52249504-52249504 19:51746251-51746251
34 FPR1 NM_002029.3(FPR1):c.582C>T (p.Ala194=)SNV Likely benign 726546 19:52249666-52249666 19:51746413-51746413
35 FPR1 NM_002029.3(FPR1):c.822C>T (p.Gly274=)SNV Benign 712949 19:52249426-52249426 19:51746173-51746173
36 FPR1 NM_002029.3(FPR1):c.289C>A (p.Leu97Met)SNV Benign 526514 rs78488639 19:52249959-52249959 19:51746706-51746706
37 FPR1 NM_002029.3(FPR1):c.645C>T (p.Ser215=)SNV Benign 526512 rs35264765 19:52249603-52249603 19:51746350-51746350
38 FPR1 NM_002029.3(FPR1):c.117C>T (p.Leu39=)SNV Benign 526510 rs149382837 19:52250131-52250131 19:51746878-51746878
39 FPR1 NM_002029.3(FPR1):c.348C>T (p.Ile116=)SNV Benign 456366 rs5030879 19:52249900-52249900 19:51746647-51746647
40 FPR1 NM_002029.3(FPR1):c.177C>T (p.Val59=)SNV Benign 456363 rs61736491 19:52250071-52250071 19:51746818-51746818
41 FPR1 NM_002029.3(FPR1):c.1037_1038delinsCA (p.Glu346Ala)indel Benign 526513 rs1555796329 19:52249210-52249211 19:51745957-51745958
42 FPR1 NM_002029.3(FPR1):c.806G>A (p.Arg269His)SNV Benign 526511 rs142210016 19:52249442-52249442 19:51746189-51746189
43 FPR1 NM_002029.4(FPR1):c.993C>T (p.Thr331=)SNV Benign 402875 rs17849971 19:52249255-52249255 19:51746002-51746002
44 FPR1 NM_002029.3(FPR1):c.488G>A (p.Arg163His)SNV Benign 456367 rs111768566 19:52249760-52249760 19:51746507-51746507
45 FPR1 NM_002029.3(FPR1):c.306T>C (p.Phe102=)SNV Benign 456365 rs28930680 19:52249942-52249942 19:51746689-51746689

Expression for Periodontitis

Search GEO for disease gene expression data for Periodontitis.

Pathways for Periodontitis

Pathways related to Periodontitis according to GeneCards Suite gene sharing:

(show top 50) (show all 81)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 TNFSF11 TNFRSF11B TNF TLR4 TLR2 MMP9
2
Show member pathways
13.74 TNFSF11 TNFRSF11B TNF TLR4 IL6 IL1B
3
Show member pathways
13.5 TNFSF11 TNF TLR4 TLR2 IL6 IL1B
4
Show member pathways
13.43 TNFSF11 TNFRSF11B TNF MMP9 MMP1 IL6
5
Show member pathways
13.36 TNFSF11 TNF IL6 IL1B IL1A IL10
6
Show member pathways
13.15 TNF TLR4 TLR2 MMP9 IL6 IL1B
7
Show member pathways
13 TNF TLR4 TLR2 IL6 IL1B CXCL8
8
Show member pathways
12.93 TNF IL6 IL1B IL1A IL10 CXCL8
9
Show member pathways
12.93 TNF TLR4 TLR2 IL6 IL1B IL1A
10
Show member pathways
12.85 TNF TLR4 TLR2 IL6 IL1B IL1A
11
Show member pathways
12.8 TNF TLR4 TLR2 IL6 IL1B IL1A
12
Show member pathways
12.72 TNF TLR4 TLR2 IL6 IL1B IL1A
13
Show member pathways
12.71 TNF TLR4 TLR2 IL6 IL1B IL1A
14
Show member pathways
12.7 TNFSF11 TNFRSF11B TNF TLR4 TLR2 IL1B
15 12.64 TNFSF11 TNF TLR2 IL1B IL10
16
Show member pathways
12.45 TNF TLR4 IL6 IL1B IL1A CXCL8
17 12.44 TNF TLR4 IL1B CXCL8
18 12.44 TNF TLR4 TLR2 IL6 IL1B CXCL8
19
Show member pathways
12.44 TNF TLR2 MMP9 MMP1 IL6 IL1B
20
Show member pathways
12.4 TNF TLR4 TLR2 IL6 IL1A CXCL8
21
Show member pathways
12.4 TNF TLR4 TLR2 IL1B IL1A IL10
22
Show member pathways
12.39 TNF IL6 IL10 CXCL8
23
Show member pathways
12.38 TNF IL6 IL1B CRP
24 12.38 TNF TLR4 IL6 IL1B CXCL8
25
Show member pathways
12.37 TNF IL6 IL1B IL1A IL10 CXCL8
26 12.36 TNF TLR4 TLR2 MMP9
27 12.35 TNF TLR4 IL6 IL1B CXCL8
28 12.34 TNF TLR4 TLR2 IL6 IL1B IL1A
29 12.32 TNF TLR4 TLR2 MMP9 MMP1 IL6
30
Show member pathways
12.31 TNF TLR4 TLR2 IL6 IL1B CXCL8
31 12.29 TNF IL6 IL1B IL1A IL10 CXCL8
32
Show member pathways
12.28 TNF IL6 IL1B IL10
33
Show member pathways
12.27 TNF TLR4 IL1B IL1A
34 12.17 TNF MMP9 IL1B IL1A
35 12.17 TNFSF11 TNFRSF11B TNF IL1B IL1A CTSK
36
Show member pathways
12.12 TLR4 TLR2 IL1B IL1A
37 12.12 TNF TLR4 IL6 IL1B IL10 CXCL8
38 12.1 TNF TLR4 MMP9 IL6 IL1B IL1A
39 12.08 TNFSF11 TNF TLR4